Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2023 | Boosting lysosomal function in microglia to treat Alzheimer’s disease

Santiago Solé-Domènech, PhD, and Rudy Gregory Jacquet, PhD Candidate, Weill Cornell Medicine, New York, NY, share their thoughts on the potential of enhancement of lysosomal function as a therapeutic strategy in Alzheimer’s disease (AD). One research focus of Dr Solé-Domènech and Mr Jacquet is lysosomal dynamics and pH in microglia, aiming to understand the role played by these processes in AD and how therapies could enhance the degradative capacity of microglia. They note that boosting lysosomal biogenesis, and consequently boosting degradation rates, could have an impact on the entire amyloidogenic cascade. Several teams are looking for small molecules that can agonize transcription factors involved in the regulation of lysososmal biogenesis. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.